#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Cystic fibrosis respiratory infection suppression Friedreich's ataxia Inclusion body myositis Adenovirus infection Neuroendocrine carcinoma metastatic Basal cell naevus syndrome Infantile apnoea B precursor type acute leukaemia Congenital pseudarthrosis Epileptic encephalopathy Germ cell cancer Nephrotic syndrome Solitary fibrous tumour Neuropathic arthropathy Acute graft versus host disease in skin More trials…

    Learn about Rare Diseases

    SAPHO syndrome – Trials in Disease Mucopolysaccharidosis II – Life with Disease Encephalitis autoimmune Gastrointestinal stromal tumour – Treatment Pemphigoid – Treatment Angiosarcoma recurrent – Treatment Castleman’s disease – Life with Disease Hairy cell leukaemia – Treatment Andersen-Tawil syndrome – Diagnostics Cytokine release syndrome – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Sodium Gluconate Riboflavin Sodium Phosphate Prednisolone Acetate L-ARGININE Ranitidine Hydrochloride BENZYLPENICILLIN PROCAINE PICLIDENOSON Gskvx000000008866 Asundexian Mps-216 Ciprofloxacin Glutenin Ipilimumab Metamizole Magnesium Dmd06-Mab Fexofenadine Folinic Acid Anselamimab Hexaminolevulinate L-LEUCINE More therapies…

    Learn about Your Condition

    Peritoneal dialysis Lung adenocarcinoma stage III Allergic respiratory disease Atrial flutter Renal cancer metastatic Hypertrophic scar Chronic sinusitis Sepsis Proteus syndrome Corticobasal degeneration Pulmonary congestion Diarrhoea Non-obstructive cardiomyopathy Colitis ulcerative Cerebellar ataxia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. IRCCS Humanitas Research Hospital

IRCCS Humanitas Research Hospital

Via Alessandro Manzoni 56, Rozzano, 20089, Italy

Want to learn more about this study or check if you can participate? Contact us.

  • Study on the Safety and Effects of AZD4831 for Adults with Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH) with Fibrosis

    Not recruiting

    2 1
    Investigated Drugs:
    • Azd4831
    Denmark Italy Norway Portugal Spain Sweden

  • Study Comparing Pembrolizumab and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Hodgkin’s disease
    Investigated Drugs:
    • Brentuximab Vedotin
    • Pembrolizumab
    Czechia France Germany Italy Poland Sweden

  • Study to Compare Mezigdomide, Carfilzomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Mezigdomide
    • Carfilzomib
    • Dexamethasone
    Austria Bulgaria Denmark Germany Greece Hungary +5

  • Study of AG-946 for Treating Anemia in Patients with Lower-Risk Myelodysplastic Syndromes

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Anaemia
    • Myelodysplastic syndrome
    Investigated Drugs:
    • Ag-946
    • Ag-946 Phosphate
    Austria Czechia France Germany Greece Italy +2

  • Study of Pembrolizumab and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Hormone-refractory prostate cancer
    • Prostate cancer metastatic
    Investigated Drugs:
    • Enzalutamide
    • Pembrolizumab
    Austria Bulgaria Czechia France Germany Hungary +5

  • Study on the Effects of MORF-057 for Adults with Moderate to Severe Ulcerative Colitis

    Not recruiting

    2 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • Morf-057
    Austria Bulgaria Czechia Estonia France Germany +7

  • Study of Pembrolizumab for Patients with Advanced Solid Tumors

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Pembrolizumab
    Denmark France Germany Italy The Netherlands Norway +3

  • Study on Ritlecitinib for Adults and Adolescents with Nonsegmental Vitiligo

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Vitiligo
    Investigated Drugs:
    • Dexamethasone
    Bulgaria Germany Italy Poland Spain

  • Study on the Effects of Eclitasertib in Adults with Moderate to Severe Ulcerative Colitis

    Not recruiting

    2 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • Eclitasertib
    Bulgaria Czechia France Germany Hungary Italy +5

  • Study of Zilovertamab Vedotin with Drug Combination for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Not recruiting

    4 1 1 1
    Investigated Drugs:
    • Bendamustine Hydrochloride
    • Gemcitabine
    • Oxaliplatin
    Denmark France Greece Italy Poland
Previous Page
1 … 61 62 63 64 65 … 69
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!